Prostate cancer

NEW --- Sequencing treatments in mCRPC patients without HRR gene mutations

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Освітня мета: Gain insight in the current treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) patients without homologous recombination repair (HRR) gene mutations.
Спеціальність: Medical oncology, Clinical oncology, Urology
Цільова аудиторія: Specialists (CME: basic, intermediate, advanced), Residents (senior)
Останнє оновлення: July 2024
Фон:

The optimal choice and sequence of life-prolonging treatments for an individual patient with mCRPC is challenging. This topic is limited to patients with a castrate serum testosterone level (<50 ng/dl or 1.7 nmol/l). Bone-protective agents fall beyond the scope of this topic.

Regulatory approval status of drugs for mCRPC discussed in this topic (indications limited to the mCRPC setting, status 26 July 2024)

This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please check your local prescribing information.